Screener
Vistagen Therapeutics, Inc.
VTGNVistagen Therapeutics is a late clinical-stage biopharmaceutical company specializing in the development of neuroscience-focused medicines.
$10.23M-88.5%
Earnings
Next report
Nov 12, 2026 (in 2 months)Revenue estimate$500.0K
EPS estimate-$0.37
Competitors
By market cap
By revenue growth
Profile
Vistagen Therapeutics is a late clinical-stage biopharmaceutical company specializing in the development of neuroscience-focused medicines. The company leverages a novel nose-to-brain neurocircuitry platform to create intranasal pherine product candidates designed to activate specific brain regions without systemic absorption or direct brain uptake.
Competitive position
Vistagen is a late-stage clinical developer with a differentiated MOA focused on rapid-acting intranasal pherines that bypass systemic absorption.
GeographiesUnited States
Customer segmentsHealthcare providers, Specialty pharmacies, Psychiatric patients
Business modelR&D-based drug development, Biotechnology licensing
SuppliersContract manufacturing organizations, Clinical research organizations, Raw material suppliers
CustomersHospitals, Psychiatric clinics, Retail pharmacies, Wholesale drug distributors
CountryUnited States of America
Listed2009
Employees37.0
CEOShawn K. Singh
SectorHealthcare
IndustryBiotechnology
Websitevistagen.com
FilingsSEC EDGAR
FAQ
- What is Vistagen Therapeutics, Inc.'s market cap?
- Vistagen Therapeutics, Inc. (VTGN) has a market capitalization of $10.2M and trades on NASDAQ.
- Who are Vistagen Therapeutics, Inc.'s competitors?
- Vistagen Therapeutics, Inc.'s key competitors include Axsome Therapeutics, Inc., Rapport Therapeutics, Inc. Common Stock, Minerva Neurosciences, Inc, and others. These companies compete in similar markets and product categories.
- Where is Vistagen Therapeutics, Inc. headquartered?
- Vistagen Therapeutics, Inc. is headquartered in United States of America and employs approximately 37 people. It has been publicly traded since 2009.